Toggle navigation
Home
Search
Services
Blog
Contact
About
Insoluble Antineoplastics Paricles for IV Injection
Violante, Michael R.
Sts Biopolymers, Inc., Henrietta, NY, United States
Search 16 grants from Michael Violante
Search grants from Sts Biopolymers, Inc.
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Comments
Recent in Grantomics:
Fred Hutchinson Cancer Research Center
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Relation of angiotensin converting enzyme (ACE) and angiotensin II (ANGII) to MRI volumetric measures from community based study
Interactions of MAO A with vulnerability factors for aggression
Inhaled Human Insulin vs Usual Subcutaneous Human Insulin Therapy in Iddm
Clinical Studies of Abnormal Host Defense
Basal Forebrain and Limbic System in Age-Related Disease
Recently added grants:
Urokinase-type plasminogen activator (uPA) in pathogenesis of lymphangioleiomyomatosis (LAM)
Predicting tuberculosis outcomes using genotypic and biomarker signatures
Circadian regulation of prefrontal cortex dependent emotional memories
Cerebellar circuits, timing, and cognition
MicroRNA regulation of angiogenesis in aging
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
2R44CA036615-02A1
Application #
3506361
Study Section
Experimental Therapeutics Subcommittee 2 (ET)
Project Start
1986-09-30
Project End
1988-09-29
Budget Start
1986-09-30
Budget End
1987-09-29
Support Year
2
Fiscal Year
1986
Total Cost
Indirect Cost
Institution
Name
Sts Biopolymers, Inc.
Department
Type
DUNS #
City
Henrietta
State
NY
Country
United States
Zip Code
14467
Related projects
NIH 1987
R44 CA
Insoluble Antineoplastics Paricles for IV Injection
Violante, Michael R. / Sts Biopolymers, Inc.
NIH 1986
R44 CA
Insoluble Antineoplastics Paricles for IV Injection
Violante, Michael R. / Sts Biopolymers, Inc.
Comments
Be the first to comment on Michael Violante's grant